EAM
AKTS

Eventide Asset Management’s Aktis Oncology AKTS Stock Holding History

Eventide Asset Management’s Portfolio AKTS Stock Details AKTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Hold
507,000
– – 0.22% 123
2026
Q1 		$9.07M Buy
+507,000
New +$9.84M 0.15% 145

Other funds holding AKTS

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Eventide Asset Management's AKTS Position: Q2 2026 in Review

Eventide Asset Management held its Aktis Oncology (AKTS) position steady in Q2 2026 at 507,000 shares worth $16.3M. The position accounts for 0.22% of the portfolio, ranked #123.

Eventide Asset Management first reported a position in AKTS in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold AKTS as of Q2 2026.

  • Eventide Asset Management held 507,000 shares of Aktis Oncology worth $16.3M as of Q2 2026.
  • Eventide Asset Management left its Aktis Oncology share count unchanged in Q2 2026.
  • Aktis Oncology made up 0.22% of Eventide Asset Management's portfolio in Q2 2026, its #123 holding.
  • Eventide Asset Management first reported a position in Aktis Oncology in Q1 2026 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Aktis Oncology as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.